Perturbation biology: inferring signaling networks in cellular systems
- PMID: 24367245
- PMCID: PMC3868523
- DOI: 10.1371/journal.pcbi.1003290
Perturbation biology: inferring signaling networks in cellular systems
Abstract
We present a powerful experimental-computational technology for inferring network models that predict the response of cells to perturbations, and that may be useful in the design of combinatorial therapy against cancer. The experiments are systematic series of perturbations of cancer cell lines by targeted drugs, singly or in combination. The response to perturbation is quantified in terms of relative changes in the measured levels of proteins, phospho-proteins and cellular phenotypes such as viability. Computational network models are derived de novo, i.e., without prior knowledge of signaling pathways, and are based on simple non-linear differential equations. The prohibitively large solution space of all possible network models is explored efficiently using a probabilistic algorithm, Belief Propagation (BP), which is three orders of magnitude faster than standard Monte Carlo methods. Explicit executable models are derived for a set of perturbation experiments in SKMEL-133 melanoma cell lines, which are resistant to the therapeutically important inhibitor of RAF kinase. The resulting network models reproduce and extend known pathway biology. They empower potential discoveries of new molecular interactions and predict efficacious novel drug perturbations, such as the inhibition of PLK1, which is verified experimentally. This technology is suitable for application to larger systems in diverse areas of molecular biology.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



















Similar articles
-
Dynamic probabilistic threshold networks to infer signaling pathways from time-course perturbation data.BMC Bioinformatics. 2014 Jul 22;15(1):250. doi: 10.1186/1471-2105-15-250. BMC Bioinformatics. 2014. PMID: 25047753 Free PMC article.
-
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.Elife. 2015 Aug 18;4:e04640. doi: 10.7554/eLife.04640. Elife. 2015. PMID: 26284497 Free PMC article.
-
Models from experiments: combinatorial drug perturbations of cancer cells.Mol Syst Biol. 2008;4:216. doi: 10.1038/msb.2008.53. Epub 2008 Sep 2. Mol Syst Biol. 2008. PMID: 18766176 Free PMC article.
-
Use of randomized sampling for analysis of metabolic networks.J Biol Chem. 2009 Feb 27;284(9):5457-61. doi: 10.1074/jbc.R800048200. Epub 2008 Oct 20. J Biol Chem. 2009. PMID: 18940807 Review.
-
Systems biology of virus-host signaling network interactions.BMB Rep. 2012 Apr;45(4):213-20. doi: 10.5483/bmbrep.2012.45.4.213. BMB Rep. 2012. PMID: 22531130 Review.
Cited by
-
Inferring regulatory networks from experimental morphological phenotypes: a computational method reverse-engineers planarian regeneration.PLoS Comput Biol. 2015 Jun 4;11(6):e1004295. doi: 10.1371/journal.pcbi.1004295. eCollection 2015 Jun. PLoS Comput Biol. 2015. PMID: 26042810 Free PMC article.
-
Estimating drivers of cell state transitions using gene regulatory network models.BMC Syst Biol. 2017 Dec 13;11(1):139. doi: 10.1186/s12918-017-0517-y. BMC Syst Biol. 2017. PMID: 29237467 Free PMC article.
-
Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations.Methods Mol Biol. 2017;1636:485-506. doi: 10.1007/978-1-4939-7154-1_30. Methods Mol Biol. 2017. PMID: 28730498 Free PMC article.
-
Applications of targeted proteomics in systems biology and translational medicine.Proteomics. 2015 Sep;15(18):3193-208. doi: 10.1002/pmic.201500004. Epub 2015 Jul 16. Proteomics. 2015. PMID: 26097198 Free PMC article. Review.
-
Systems biology approaches for advancing the discovery of effective drug combinations.J Cheminform. 2015 Feb 26;7:7. doi: 10.1186/s13321-015-0055-9. eCollection 2015. J Cheminform. 2015. PMID: 25741385 Free PMC article.
References
-
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674. - PubMed
-
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous